Student presentation on importance and challenges of cannabis research
The penultimate week of my Marijuana Law and Policy seminar at The Ohio State University Moritz College of Law will include five more student presentations on the students’ selected research topics. Students continue to provide here a brief summary and some background reading for their classmates about their planned presentation, and here is the first summary post with links for this coming week’s first presentation:
While contemporary policy often emphasizes clinical trials, medical efficacy, and therapeutic formulations, marijuana research does not begin at the clinical phase. The pre-clinical research pipeline impacts the landscape of marijuana policy by generating the foundational knowledge upon which clinical, regulatory, and public health decisions depend. Early research studies provide necessary precursor knowledge about cannabinoid chemistry, mechanisms of action, toxicology, dosing, and product quality. This work guides what questions are asked in clinical trials, how those trials are designed, and how their results are interpreted. Furthermore, cannabis science informs broader considerations including public perceptions of safety and criminal law.
Discussions on cannabis research tend to understate how legal and policy frameworks constrain research outside of the clinical environment. Restricted access to federally authorized cannabis limits researchers to narrow and often unrepresentative samples, failing to capture the diversity and chemical complexity of marijuana used by the public. This disconnect undermines the validity and applicability of scientific findings. At the same time, regulatory requirements impose rigidity that discourages the iterative and adaptive approaches central to sound scientific practice. Funding constraints, institutional risk aversion, and legal ambiguity further compound these issues, shaping which projects are pursued, what data is obtainable, and who can participate in research.
As a result, significant gaps remain in the scientific understanding of cannabis. Many studies are limited in scope or difficult to replicate, industry methodologies are inconsistent, and funding sources can skew findings. Weaknesses at the foundational level propagate downstream, producing inconsistency and uncertainty that can influence decades of future decisions. Efforts to advance marijuana policy while neglecting the informational foundation driving progress risks preventable failures and undermined credibility. Pre-clinical research may not always yield eye-catching headlines, but it is essential for developing sustainable policy over time.
Recommended Background Reading: